Skip to main content
Clinical Trials/CTRI/2025/08/093492
CTRI/2025/08/093492
Not yet recruiting
Not Applicable

To evaluate quality of life (QOL) in patients undergoing multivisceral resections and/or vascular resections for retroperitoneal sarcomas.

Tata Memorial Hospital, Mumbai1 site in 1 country100 target enrollmentStarted: September 8, 2025Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Tata Memorial Hospital, Mumbai
Enrollment
100
Locations
1
Primary Endpoint
To evaluate Long-term ( more than 8 weeks) QOL in patients undergoing multivisceral and/or vascular resections for RP sarcomas

Overview

Brief Summary

Type of study: Retrospective and Prospective study

 This study aims to evaluate the quality of life (QOL) in patients undergoing multivisceral resections and/or vascular resections for retroperitoneal sarcomas. Retroperitoneal sarcomas are rare tumors that develop in the space behind abdominal organs and can grow to substantial sizes before causing symptoms. Due to their proximity to critical organs and blood vessels, surgical removal often requires extensive procedures involving multiple organs or blood vessel reconstruction. While surgery is essential for improving survival, it can lead to complications that significantly impact the physical, emotional, and social well-being of patients.

The study will assess both short-term and long-term outcomes, including post-operative complications such as kidney issues, bowel dysfunction, pain, weakness, and hospital readmissions. In the longer term, it will evaluate changes in renal function, nutritional status, limb strength, and the need for prolonged medication. Quality of life will be measured using the widely recognized EORTC QLQ-C30 questionnaire, which evaluates physical, emotional, and social functioning alongside symptoms experienced by patients after cancer treatment. Researchers will collect data retrospectively from January 2016 to January 2025 and prospectively until June 2026, covering a total of 200 patients.

The ethical aspects of this research will be carefully managed, with informed consent obtained from participants in a language they understand. Confidentiality and data privacy will be strictly maintained. Institutional ethics committee approval will be sought, and adverse events will be reported according to regulatory guidelines. The study will adhere to international and institutional standards for patient safety and research integrity.

By identifying key factors influencing recovery and quality of life, this research is expected to guide better clinical decision-making for patients undergoing complex surgeries for retroperitoneal sarcomas. The development of a sarcoma-specific QOL scoring system may help healthcare providers improve treatment strategies and patient support in both short- and long-term settings.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18.00 Year(s) to 99.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • All patients who can be contacted in person or telephonically
  • All patients over 18-years of age, undergoing Multi-visceral resections for RP sarcomas
  • All patients undergoing Vascular resection (with/ without reconstructions) for RP sarcomas.

Exclusion Criteria

  • 1.Other RP tumors (non-sarcomas) 2.Patients not willing to participate in the study/ cannot give a valid informed consent.

Outcomes

Primary Outcomes

To evaluate Long-term ( more than 8 weeks) QOL in patients undergoing multivisceral and/or vascular resections for RP sarcomas

Time Frame: day 0 on the day of enrollment, 3 months and 6 months after enrollment

Secondary Outcomes

  • To evaluate short-term outcomes (less than 8 weeks) as Post op morbidity, Post-op Ileus, Acute renal failure, Diarrhoea, Clinically significant chyle leaks, Limb weakness, Lower limb edema , Length of ICU stay, ICU re-admission rates, Length of hospital stay, Hospital readmission rates, Re-operation rates, Fitness for adjuvant chemo(day 0 on the day of enrollment, 3 months and 6 months after enrollment)

Investigators

Sponsor
Tata Memorial Hospital, Mumbai
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

Dr Mahesh Goel

Tata Memorial Hospital, Mumbai-12

Study Sites (1)

Loading locations...

Similar Trials